| VOYAGER THERAPEUTICS |
| USA |
| Gesundheit |
| US92915B1061 / A143XJ |
| VT6 (Frankfurt) / VYGR (NASDAQ) |
| FRA:VT6, ETR:VT6, VT6:GR, NASDAQ:VYGR |
| - |
| https://www.voyagertherap.. |
|
Voyager Therapeutics Inc. operates as a biotechnology company focusing on developing gene therapies for severe neurological diseases and other disorders. The company's primary purpose is to harness the potential of gene therapy to transform the treat..
>Volltext.. |
| 206.01 Mio. EUR |
| 69.89 Mio. EUR |
| 34.98 Mio. EUR |
| -110.7 Mio. EUR |
| -103.72 Mio. EUR |
| -1.77 EUR |
| 31.62 Mio. EUR |
| 56.57 Mio. EUR |
| -114.76 Mio. EUR |
| 7.4 |
| -55.52% |
| -62.34% |
| - |
| - |
| - |
| VOYAGER THERAPEUTICS, VOYAGER THERAPEUTIC |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|